{"id":893733,"date":"2025-10-08T08:54:11","date_gmt":"2025-10-08T12:54:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/"},"modified":"2025-10-08T08:54:11","modified_gmt":"2025-10-08T12:54:11","slug":"vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/","title":{"rendered":"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Oct.  08, 2025  (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (OTCQX: VXRT) (\u201cVaxart\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025.<\/p>\n<p align=\"justify\">Vaxart\u2019s mission is to improve global public health by developing a transformative oral pill vaccine platform. With multiple promising clinical-stage programs, including those targeting norovirus and COVID-19, the Company is committed in solving serious health challenges facing society. Vaxart\u2019s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable safety and tolerability profile in clinical trials, reinforcing its potential of bringing worldwide game changing solutions.<\/p>\n<p align=\"justify\">\n        <strong>Presentation Information:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong>Oral bivalent vaccine for norovirus protection. Recent improvements to improve immunogenicity and potentially efficacy<br \/><strong>Speaker: <\/strong>Dr. Sean Tucker, Founder and Chief Scientific Officer<br \/><strong>Date: <\/strong>Wednesday, October 15<br \/><strong>Time:<\/strong> 11:45 a.m. CEST<br \/><strong>Location<\/strong>: Track 1<\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong>Oral Covid Vaccine &#8211; Clinical update from phase 1 to phase 2B<br \/><strong>Speaker: <\/strong>Dr. Sean Tucker, Founder and Chief Scientific Officer<br \/><strong>Date: <\/strong>Wednesday, October 15<br \/><strong>Time:<\/strong> 3:45 p.m. CEST<br \/><strong>Location<\/strong>: Track 5<\/p>\n<p align=\"justify\">\n        <strong>About Vaxart<br \/><\/strong>Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart\u2019s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart\u2019s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.<\/p>\n<p align=\"justify\">\n        <strong>Note Regarding Forward-Looking Statements <\/strong><br \/>\n        <br \/>This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d) and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), which are subject to the \u201csafe harbor\u201d created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management\u2019s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under \u201cItem 1A &#8211; Risk Factors\u201d in our Annual Report on Form 10-K for the year ended December 31, 2024 and risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this communication.<\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<p>\n        <strong>Vaxart Media and Investor Relations<\/strong><br \/>\n        <br \/>Matt Steinberg<br \/>FINN Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vEXZrwwYe6t76qhH7WC2TItjoxBkB1yLHmAq5d3TCaXGH6M1-N5JETt9oJILEz_sUCCLTSNrJEqaUaKW03PrGA==\" rel=\"nofollow\" target=\"_blank\">IR@vaxart.com<\/a><br \/>(646) 871-8481<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjUyODFiNGYtODBiOS00ZjA5LWFlYTEtZmZkN2Y1MDA0ODU3LTEwMzA2ODItMjAyNS0xMC0wOC1lbg==\/tiny\/Vaxart-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (OTCQX: VXRT) (\u201cVaxart\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025. Vaxart\u2019s mission is to improve global public health by developing a transformative oral pill vaccine platform. With multiple promising clinical-stage programs, including those targeting norovirus and COVID-19, the Company is committed in solving serious health challenges facing society. Vaxart\u2019s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-893733","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (OTCQX: VXRT) (\u201cVaxart\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025. Vaxart\u2019s mission is to improve global public health by developing a transformative oral pill vaccine platform. With multiple promising clinical-stage programs, including those targeting norovirus and COVID-19, the Company is committed in solving serious health challenges facing society. Vaxart\u2019s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable &hellip; Continue reading &quot;Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-08T12:54:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025\",\"datePublished\":\"2025-10-08T12:54:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/\"},\"wordCount\":714,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/\",\"name\":\"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=\",\"datePublished\":\"2025-10-08T12:54:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/","og_locale":"en_US","og_type":"article","og_title":"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (OTCQX: VXRT) (\u201cVaxart\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025. Vaxart\u2019s mission is to improve global public health by developing a transformative oral pill vaccine platform. With multiple promising clinical-stage programs, including those targeting norovirus and COVID-19, the Company is committed in solving serious health challenges facing society. Vaxart\u2019s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable &hellip; Continue reading \"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-08T12:54:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025","datePublished":"2025-10-08T12:54:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/"},"wordCount":714,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/","name":"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=","datePublished":"2025-10-08T12:54:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTc0NCM3MTg0NDE4IzIwMTkxMDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-showcase-its-norovirus-and-covid-19-oral-pill-vaccine-candidates-at-world-vaccine-congress-europe-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=893733"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893733\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=893733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=893733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=893733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}